Alex Sapir, President & CEO, Director at Dova Pharmaceuticals, holds 43.36K shares in Fulcrum Therapeutics (Ticker: FULC), holds 3.75K shares in Phasebio Pharmaceuticals (Ticker: PHASQ), holds 68.61K shares in Dova Pharmaceuticals (Ticker: DOVA). Most recently, Alex Sapir Bought ― shares of Fulcrum Therapeutics on Mar 05, 2024 for an estimated value of 491.70K.